NCT03828799View on ClinicalTrials.gov

Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 14, 2019

Primary Completion Date

December 2, 2021

Study Completion Date

November 30, 2024

Conditions

Metastatic Colorectal Cancer

Interventions

COMBINATION_PRODUCT

Folfirinox + regorafenib

folfirinox : from day 1 to day 3 regorafenib : day 4 to day 10 a cycle during 14 days

Trial Locations (4)

21079

Centre Georges-François Leclerc, Dijon

22190

Centre Cario - HPCA, Plérin

34298

Institut du Cancer de Montpellier - Val d'Aurelle, Montpellier

06189

Centre Antoine Lacassagne, Nice

All Listed Sponsors

lead

Institut du Cancer de Montpellier - Val d'Aurelle

OTHER

NCT03828799 - Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer | Biotech Hunter | Biotech Hunter